(Q40963930)

25 September 2017

1 reference

title

Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard (English)

1 reference

25 September 2017

Furst DE

1

1 reference

25 September 2017

publication date

1 November 1995

1 reference

Bailliere's clinical rheumatology

25 September 2017

published in

1 reference

25 September 2017

volume

9

1 reference

25 September 2017

issue

4

1 reference

25 September 2017

page(s)

711-729

1 reference

A randomised double-blind trial of cyclosporin and azathioprine in refractory rheumatoid arthritis

25 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Cyclosporine pharmacokinetic drug interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Cyclosporine: nephrotoxic effects and guidelines for safe use in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Cyclosporin in rheumatoid arthritis: a double blind, placebo controlled study in 52 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Bromocriptine and cyclosporin A combination therapy in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Nitrogen mustard in treatment of systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Radiologic evidence of disease modification in rheumatoid arthritis patients treated with cyclosporine. Results of a 48-week multicenter study comparing low-dose cyclosporine with placebo. Norwegian Arthritis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Lymphokine gene expression in vivo is inhibited by cyclosporin A.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

The treatment of persistent synovitis with nitrogen mustard

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Nitrogen mustard and methylprednisolone in severe rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Nitrogen mustard in severe rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

A randomized, double-blind, 24-week controlled study of low-dose cyclosporine versus chloroquine for early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

DNA as a target of alkylating carcinogens

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

The effect of food on cyclosporine absorption

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Clinical pharmacokinetics of cyclosporin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Intravenous administration of nitrogen mustard alone and with corticotropin for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Prolonged remission of tumor-stage mycosis fungoides by topical immunotherpay

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Use of nitrogen mustard in treatment of serous effusions of neoplastic origin

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

Pharmacokinetic drug interactions with cyclosporin (Part II).

1 reference

https://api.crossref.org/works/10.1016%2FS0950-3579%2805%2980310-3

7 January 2021

10.1016/S0950-3579(05)80310-3

Identifiers

DOI

1 reference

25 September 2017

1 reference